

Patient Organisation disclosure template 2024						
PO name	Country	Types of the support or services provided	Description of the support or services 1	Monetary value of financial support and of invoiced costs	Non-monetary benefit for PO ₂	Fees for services paid
Arthritis Ireland	Ireland	Financial support	Johnson and Johnson Innovative Medicine provided €10,000 to support Arthritis Ireland's Clinical Referral Programme and its Information stand	10,000	0	0
Barnardos Ireland	Ireland	Financial support	Johnson and Johnson CSR_Barnardos_ Charitable	20,000	0	0
CLL Ireland	Ireland	Financial Support	Johnson and Johnson Innovative Medicine provided funding to CLL Ireland to support two patient information meetings and a patient booklet	7,700	0	0
Fighting Blindness	Ireland	Financial support	Johnson & Johnson Innovative Medicine paid sponsorship to Fighting Blindness Ireland for the RIWC 2024	100,000	0	0
IPPOSI	Ireland	Financial support	Johnson & Johnson Innovative Medicine provided €10,000 for 2024 membership of IPPOSI	10,000	0	0
Irish Soc Colitis/Crohns Dis	Ireland	Financial support	Johnson & Johnson Innovative Medicine provided €7,000 to Crohn's and Colitis Ireland to support a patient information meeting in Cork in May 2024 and the development and distribution of its membership magazine	7,000	0	0
Multiple Myeloma Ireland	Ireland	Financial support	Johnson and Johnson Innovative Medicine provided €10,000 to Multiple Myeloma Ireland towards their patient information day, podcast and research grants in 2024	10,000	0	0
Rare Diseases Ireland	Ireland	Financial support	Johnson & Johnson Innovative Medicine provided €5000 to support Rare Disease Ireland's Rare Disease Day event in February 2024.	5,000	0	0
Retina International	Ireland	Financial support	Johnson & Johnson Innovative Medicine provided funding to Retina International for various project activities in 2024	100,000	0	0
Retina International	Ireland	Financial support	Johnson & Johnson Global provided funding to Retina International for activation arounds RI's report on impact of wet age-related macular degeneration and geography	6,628	0	0
Retina International	Ireland	Financial support	Johnson & Johnson Innovative Medicine provided €22,500 to Retina International for a Perspectives Study	22,500	0	0
Retina International	Ireland	Financial support	Johnson & Johnson Innovative Medicine provided €30,000 to Retina International for a Retina Patient Education Hub	30,000	0	0
Arthritis Ireland	Ireland	Contracted services	Johnson and Johnson Innovative Medicine paid a fee for service to Arthritis Ireland for participating in a Patient Connect event with staff at its Cork site.	0	0	455
CLL Ireland	Ireland	Contracted services	Johnson and Johnson Innovative Medicine paid CLL Ireland to participate on a steering committee to discuss criteria to define CLL patient characteristics and how to define patient	0	0	440
CLL Ireland	Ireland	Contracted services	Johnson and Johnson Innovative Medicine paid CLL Ireland to participate in meeting to review expert opinion from EHA steering committee meeting output	0	0	385
IPPOSI	Ireland	Contracted services	Johnson and Johnson Innovative Medicine provided a fee for service to IPPOSI for time spent preparing and speaking at a patient organisation webinar	0	0	605
Irish Soc Colitis/Crohns Dis	Ireland	Contracted services	Johnson and Johnson Innovative Medicine provided a fee for service to Crohn's and Colitis Ireland for time spent on recording and promoting an episode of Gutcast	0	0	3,640
Multiple Myeloma Ireland	Ireland	Contracted services	Johnson and Johnson Innovative Medicine paid a fee for service to Multiple Myeloma Ireland for a representative to speak at an internal staff event	0	0	192.50
Multiple Myeloma Ireland	Ireland	Contracted services	Johnson and Johnson Innovative Medicine paid Multiple Myeloma Ireland to participate in an advisory board to develop patient facing resources relating to the practical management of common side effects	0	0	495
Retina International	Ireland	Contracted services	Johnson & Johnson Innovative Medicine paid Retina International for preparatory work for a ISPOR Educational symposium	0	0	600
Retina International	Ireland	Contracted services	Johnson & Johnson Innovative Medicine provided a fee to Retina International to participate in EMF 2024 - Patient Interview	0	0	750
Retina International	Ireland	Contracted services	Johnson & Johnson Innovative Medicine provided a fee to Retina International to participate at MAF_2024_EMEA Diagnostic Adboard	0	0	1,720
Retina International	Ireland	Contracted services	Johnson & Johnson Innovative Medicine provided a fee to Retina International to participate at a Discounting round table meeting	0	0	1,350
Retina International	Ireland	Contracted services	Johnson & Johnson Innovative Medicine provided a fee for service for two members of Retina International to participate in an advisory meeting	0	0	1,950

1: Add a clear description of the purpose of the support or services

2: For example, employee hours or companies facilities offered to support a Patient Organisation activity

Johnson & Johnson Innovative Medicine

Johnson & Johnson Innovative Medicine (J&J) disclosure methodology for 2024 (Patient Organisations)

1. Introduction

The information below describes the methodology that Janssen Sciences Ireland UC, Pharmaceutical companies of Johnson & Johnson (J&J) has applied to disclose the Transfers of Value (ToV) made to Patient Organisations (POs) in the submission to the Irish Pharmaceutical Healthcare Association (IPHA) for 2024.

2. Which payments will be included?

The following types of payments to identified POs (as defined in Annex 3 of the IPHA Code of Practice for the Pharmaceutical Industry) are disclosed:

- Funding may be provided for a PO publication, meeting, project or piece of research in which the company has little or no involvement;
- A company may facilitate PO meetings by providing or sponsoring speakers or providing a venue or making a contribution towards travel expenses for delegates;
- A company may undertake projects of joint interest with a PO.

In addition to payments defined by the IPHA code, J&J will also include

- Fee for services- Payments made to POs for their time and contributions to J&J work/projects

3. What rules have J&J applied to be included for disclosure?

The following rules apply:

- All direct and indirect payments to POs will be included in the calendar year in which J&J executed the payment in our financial systems.

4. How does J&J report non-monetary value for ToV for benefits in kind made to POs?

J&J discloses benefits in kind using the fair market value listed in the contract between J&J and the PO.

Johnson & Johnson Innovative Medicine

5. How does J&J report ToV related to multi-year contracts?

For contracts that span multiple years, typically a split payment approach is used. This means that the total value is transferred in separate payments over time.

Each of these separate payments will be included in J&J disclosure numbers for the calendar year in which J&J executed the actual payment in our financial systems.

6. Is VAT included?

Direct payments are disclosed exclusive of VAT and inclusive of withholding tax, if applicable.

All ToVs for travel and accommodation (e.g., flight ticket, hotel room, etc.) are reported inclusive of VAT, where applicable.

The disclosure reported ToV amounts should not be used for VAT/Tax reporting purposes. If fiscal reports are required, the company provides them directly to the POs.

7. Which J&J companies have a duty to disclose ToVs?

J&J is a member of the IPHA. J&J has a code requirement to disclose all ToVs made to POs based in Ireland.

Disclaimer

J&J relies on a combination of automated systems, standardised processes, and manual data entry from internal and external resources to record and report relevant ToV data. The information reported in this submission is done in good faith and best efforts to comply with the requirements of the IPHA Disclosure Code. Although J&J strive for efficient and fast processing, it might occur that payment information becomes available only after the date of publishing. Should we, despite our best efforts to ensure accurate reporting, fail to include complete and correct information in our submission, we will appropriately investigate and address in case of erroneous information. J&J expect this to be exceptional and will monitor actual occurrences. In case of significant changes to the initial publication J&J will publish an amendment within a reasonable timeframe.

Johnson & Johnson Innovative Medicine

Should a PO consider that the report is incomplete or incorrect, please contact us via disclosure@janssen.ie and we will make appropriate changes as soon as possible.

Date of Preparation: April 2025 Item Code: CP-231368 V.6